Yiping Zhang - Concepedia

Author

Yiping Zhang

Also Known As

Kun Yu, Rui Meng, Yan Zhang, Yi Ping Zhang, Yi-Ping ZHANG, Yi-Ping Zhang, Yi-ping ZHANG, Yi-ping Zhang, Yiping ZHANG, Yiping ZhANG

385

Publications

8.5K

Citations

H-Index

327

Concepts

All Affiliations

Zhejiang University Zhejiang Cancer Hospital Peking University University of Alberta Chinese Academy of Medical Sciences & Peking Union Medical College

About

Yiping Zhang is an author at Zhejiang University specializing in engineering, medicine, and chemistry.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Engineering	36	87	3.5K
2	Medicine	24	34	2.5K
3	Health Sciences	8	8	700
4	Natural Sciences	6	6	380
5	Public Health	3	3	112

Yiping Zhang

169

Publications

7.6K

Citations

H-Index

Page 1

	Year	Citations
Camrelizumab plus carboplatin and pemetrexed versus chemotherapy alone in chemotherapy-naive patients with advanced non-squamous non-small-cell lung cancer (CameL): a randomised, open-label, multicentre, phase 3 trial Caicun Zhou, Gongyan Chen, Yunchao Huang, The Lancet Respiratory Medicine OncologyClinical TrialsChemotherapy-naive PatientsImmune Checkpoint InhibitorPharmacotherapy	2020	488
Camrelizumab Plus Carboplatin and Paclitaxel as First-Line Treatment for Advanced Squamous NSCLC (CameL-Sq): A Phase 3 Trial Shengxiang Ren, Jianhua Chen, Xingxiang Xu, Journal of Thoracic Oncology Camrelizumab Plus CarboplatinMedicineAdvanced Squamous NsclcPharmacologyClinical Trials	2021	293
Tepotinib plus gefitinib in patients with EGFR-mutant non-small-cell lung cancer with MET overexpression or MET amplification and acquired resistance to previous EGFR inhibitor (INSIGHT study): an open-label, phase 1b/2, multicentre, randomised trial Yi‐Long Wu, Ying Cheng, Jianying Zhou, The Lancet Respiratory Medicine OncologyMet AmplificationMedicinePathologyPhase 1B/2	2020	249
EGFR mutation prevalence in Asia-Pacific and Russian patients with advanced NSCLC of adenocarcinoma and non-adenocarcinoma histology: The IGNITE study Baohui Han, Sergei Tjulandin, Koichi Hagiwara, Lung Cancer Advanced NsclcEgfr Mutation PrevalenceMedicinePathologyIgnite Study	2017	149
Clinical and biomarker analyses of sintilimab versus chemotherapy as second-line therapy for advanced or metastatic esophageal squamous cell carcinoma: a randomized, open-label phase 2 study (ORIENT-2) Jianming Xu, Yi Li, Qingxia Fan, Nature Communications	2022	147
Dry heating and annealing treatment synergistically modulate starch structure and digestibility Chengdeng Chi, Xiaoxi Li, Ping Lu, International Journal of Biological Macromolecules EngineeringDry HeatingBiochemical EngineeringThermal ProcessingFood Processing	2019	137
Efficacy, safety, and biomarker analysis of ensartinib in crizotinib-resistant, ALK-positive non-small-cell lung cancer: a multicentre, phase 2 trial Yunpeng Yang, Jianya Zhou, Jianying Zhou, The Lancet Respiratory Medicine Biomarker AnalysisMedicinePharmacologyPathologyBronchial Neoplasm	2019	135
From Zn(OH)2 to ZnO: a study on the mechanism of phase transformation Mingsong Wang, Yajun Zhou, Yiping Zhang, CrystEngComm Phase TransitionsIntermediate Growth StageEngineeringCrystal Growth TechnologySolid-state Chemistry	2011	124
Physical Modeling on Sand Erosion around Defective Sewer Pipes under the Influence of Groundwater Shuai Guo, Yu Shao, Tuqiao Zhang, Journal of Hydraulic Engineering EngineeringGeotechnical EngineeringSand ErosionErosion PredictionDebris Flow	2013	121
Efficacy, safety, and genetic analysis of furmonertinib (AST2818) in patients with EGFR T790M mutated non-small-cell lung cancer: a phase 2b, multicentre, single-arm, open-label study Yuankai Shi, Xingsheng Hu, Shucai Zhang, The Lancet Respiratory Medicine Genetic AnalysisEgfr T790mPhase 2BMedicineImmunology	2021	115

Page 1